European biotech boss on Brexit: we won't partner with UK labs

The boss of one of Europe’s leading biotech companies tells The Pharma Letter that it cannot now consider teaming up with UK researchers because of fears that such partnerships will lose European Union (EU) funding.

It follows the decision of UK voters to exit the EU in last week’s referendum.

Stephane Boissel, chief executive of French biotech company TxCell (Euronext Paris: TXCL), had warned about the consequences of Brexit before the vote. His comments afterwards in an exclusive interview with The Pharma Letter, which he calls a perspective from the heart of the European biotech community, will do nothing to calm any fears held by UK researchers, whose concerns also came up in questions in the UK parliament on Monday.